, Tracking Stock Market Picks
Enter Symbol:
Rating: CA
Overweight $33
down 17.00 %

Ca Inc. (NASDAQ: CA) reiterated to Overweight with price target $33 by Barclays

Tuesday,  Jan 12, 2016  12:25 PM ET by Lynn Gilbert

Barclays reiterated Ca Inc. (NASDAQ: CA) to Overweight with price target $33. Previously, Barclays rated Ca Inc. (NASDAQ: CA) to Equal Weight with price
target $35 on 04/01/2015, when the stock price was valued at $32.03. Since then, Ca Inc.'s stock price has lost 17% as of 01/12/2016's recent price of $26.51.
If you had followed Barclays's previous recommendation on CA, you would have lost 17% of your investment in 286 days.

Careside has developed and plans to sell a proprietary blood testing systemcalled the Careside system. It is designed to decentralize laboratoryoperations. The system consists of a testing instrument called the CareSideAnalyzer and disposable test cartridges. It performs blood tests in the same location as the patient, or what is commonly called point-of-care testing. The company's goal is to make decentralized testing with the Careside system the standard for routine and critical care blood testing.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy